These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 15035885)
1. Are there differences in breast tissue as a result of hormone replacement therapy? Can BEST imaging distinguish these differences? Fleming RM Integr Cancer Ther; 2003 Sep; 2(3):229-34. PubMed ID: 15035885 [TBL] [Abstract][Full Text] [Related]
2. Do women taking hormone replacement therapy (HRT) have a higher incidence of breast cancer than women who do not? Fleming RM Integr Cancer Ther; 2003 Sep; 2(3):235-7. PubMed ID: 15035886 [TBL] [Abstract][Full Text] [Related]
3. What effect, if any, does soy protein have on breast tissue? Fleming RM Integr Cancer Ther; 2003 Sep; 2(3):225-8. PubMed ID: 15035884 [TBL] [Abstract][Full Text] [Related]
4. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377 [TBL] [Abstract][Full Text] [Related]
5. Breast enhanced scintigraphy testing distinguishes between normal, inflammatory breast changes, and breast cancer: a prospective analysis and comparison with mammography. Fleming RM; Dooley WC Integr Cancer Ther; 2002 Sep; 1(3):238-45. PubMed ID: 14667282 [TBL] [Abstract][Full Text] [Related]
6. Mitochondrial uptake of sestamibi distinguishes between normal, inflammatory breast changes, pre-cancers, and infiltrating breast cancer. Fleming RM Integr Cancer Ther; 2002 Sep; 1(3):229-37. PubMed ID: 14667281 [TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and the risk of breast lesions that predispose to cancer. Cahn MD; Tran T; Theur CP; Butler JA Am Surg; 1997 Oct; 63(10):858-60. PubMed ID: 9322657 [TBL] [Abstract][Full Text] [Related]
8. Case-control study of increased mammographic breast density response to hormone replacement therapy. Vachon CM; Sellers TA; Vierkant RA; Wu FF; Brandt KR Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1382-8. PubMed ID: 12433715 [TBL] [Abstract][Full Text] [Related]
9. Benign breast diseases, contraception and hormone replacement therapy. Gadducci A; Guerrieri ME; Genazzani AR Minerva Ginecol; 2012 Feb; 64(1):67-74. PubMed ID: 22334232 [TBL] [Abstract][Full Text] [Related]
10. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. Topal NB; Ayhan S; Topal U; Bilgin T J Obstet Gynaecol Res; 2006 Jun; 32(3):305-8. PubMed ID: 16764621 [TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone replacement therapy: endometrial and breast effects. Yeh IT Adv Anat Pathol; 2007 Jan; 14(1):17-24. PubMed ID: 17198307 [TBL] [Abstract][Full Text] [Related]
12. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277 [TBL] [Abstract][Full Text] [Related]
13. [Hormone replacement therapy and breast cancer]. Dobashi K Gan To Kagaku Ryoho; 1999 Jun; 26(7):871-6. PubMed ID: 10396312 [TBL] [Abstract][Full Text] [Related]
14. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781 [TBL] [Abstract][Full Text] [Related]
15. Influence of menopausal status and use of hormone replacement therapy on radiation dose from mammography in routine breast screening. Whitaker CJ; Kelly CM; Faulkner K; Stamp EC Br J Radiol; 2006 Jul; 79(943):597-602. PubMed ID: 16823065 [TBL] [Abstract][Full Text] [Related]
16. Risk of breast cancer in post-menopausal women using hormone replacement therapy. Ratanawichitrasin A; Reansuwan W; Ratanawichitrasin S; Bhodhisuwan K; Kongpatanakul S J Med Assoc Thai; 2002 May; 85(5):583-9. PubMed ID: 12188389 [TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations. Delille JP; Slanetz PJ; Yeh ED; Kopans DB; Halpern EF; Garrido L Radiology; 2005 Apr; 235(1):36-41. PubMed ID: 15798166 [TBL] [Abstract][Full Text] [Related]
18. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414 [TBL] [Abstract][Full Text] [Related]
19. Evaluating hormone therapy-associated increases in breast density comparison between reported and simultaneous assignment of BI-RADS categories, visual assessment, and quantitative analysis. Harvey JA; Bovbjerg VE; Smolkin ME; Williams MB; Petroni GR Acad Radiol; 2005 Jul; 12(7):853-62. PubMed ID: 16039539 [TBL] [Abstract][Full Text] [Related]
20. Atypical hyperplasia, proliferative fibrocystic change, and exogenous hormone use. Zera RT; Danielson D; Van Camp JM; Schmidt-Steinbrunn B; Hong J; McCoy M; Anderson WR; Linzie BM; Rodriguez JL Surgery; 2001 Oct; 130(4):732-7. PubMed ID: 11602905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]